Studies gut bacteria in people with spondyloarthritis receiving TNF-inhibitor treatment
Observes gut bacteria and disease activity in adults with spondyloarthritis on TNF-inhibitor therapy.
Plain-language title generated from the registry record
Registry title: Faecal Analyses in Spondyloarthritis Therapy
Key facts
- Where
- Lund, SwedenSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with spondyloarthropathy who are about to start TNF-inhibition treatment. It follows their gut bacteria and how well the treatment works.
- Age
- 18 Years or older
- Sex
- All sexes can join.
- Disease stage
- Spondyloarthropathy that meets the Assessment of SpondyloArthritis International Society classification criteria.
- Earlier treatment
- About to start TNF-inhibition treatment. People on ongoing biological therapy cannot join.
Main reasons for not taking part
- Failure to understand the protocol
- A history of alcohol abuse
- Any history of diverticulitis
- A history of failure to comply with prescribed medication
- Ongoing biological therapy
Read by machine on 9 November 2026.
Where in Sweden
- Reumatologi SUS Lund, Region SkåneLund, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Region Skane
- Trial code
- NCT03839862
- Record updated
- 6 March 2024
- Original description
This study evaluates the intestinal microbiome and disease activity in patients with spondyloarthropathies receiving immunosuppressive therapy.Read full original descriptionShow less
Faecal Analyses in Spondyloarthritis Therapy: A Prospective Observational Study of the Intestinal Microbiome in Patients With Spondyloarthropathy Receiving TNF-inhibition.
This study evaluates the intestinal microbiome and disease activity in patients with spondyloarthropathies receiving immunosuppressive therapy.
Patients will be analysed at two time points in reference to two predefined primary endpoints:
* Changes in intestinal microbiome * Response to therapy
The investigators want to evaluate if successful treatment of spondylarthropathy coincide with specific changes in the gut flora.
Inclusion: Fulfilling the Assessment of SpondyloArthritis International Society classification criteria for spondyloarthropathy; About to commence treatment with TNF-inhibition.
Exclusion: Ongoing biological therapy; Failure to understand protocol; A history of alcohol abuse; Any history of diverticulitis; A history of failure to comply with prescribed medication.